Ichor Life Sciences completes acquisition of Woodland Biosciences

LAFAYETTE, N.Y. — Ichor Life Sciences, based in LaFayette, has completed its acquisition of Woodland Biosciences, Inc. of Massachusetts.

The in-vivo services for the study of metabolic diseases and oncology provided by the former Woodland Biosciences are now available through Ichor’s Pharmacology division, per a company news release.

The companies didn’t disclose any financial terms of this acquisition agreement.

Ichor Life Sciences describes itself as a preclinical contract-research organization offering services in discovery through pharmacology.

Ichor describes Woodland Biosciences as a preclinical contract-research organization. It was previously located on the campus of Tufts Veterinary Medicine School in North Grafton, Massachusetts.

Woodland’s research and development (R&D) facilities have fully relocated from Tufts University to Ichor’s facilities in LaFayette. Michael Briggs, the president of Woodland Biosciences, is now part of Ichor’s scientific leadership in pharmacology.

Briggs has “deep expertise and experience” in pharmacology and has worked on several preclinical and clinical programs in hepatitis, liver fibrosis and oncology, among others, Ichor said.

“Woodland Biosciences’ capabilities in developing orthotopic and syngeneic models with a focus on liver and pancreatic cancers, along with models in NASH and other metabolic diseases, expands the specialization within our Ichor Pharmacology group,” Kelsey Moody, CEO of Ichor Life Sciences, said. “As we seek to continuously add to our portfolio of services and broaden our expertise, we plan to identify other opportunities for acquisitions in the months ahead.”